The medication Mavenclad shows good long-term results.
Three-fourths of relapsing multiple sclerosis (MS) patients who took two short courses of Mavenclad (cladribine tablets) over two years remained relapse-free for four years, according to newly published data from the medication’s Phase 3 extension trial.
Moreover, patients who took Mavenclad during the first two years and then a placebo for the next two years fared similarly to those who took Mavenclad for the entire four-year period.
The report, “Safety and efficacy of cladribine tablets in patients with relapsing–remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study,” appeared in the Multiple Sclerosis Journal.
“Today’s publication further strengthens the evidence for the use of Mavenclad in MS, demonstrating significant, durable benefits in patients not receiving active treatment after the two short courses,” lead investigator Gavin Giovannoni, chair of neurolog at Barts and The London School of Medicine and Dentistry, said in a press release.
|Read Full Article: Relapsing MS Patients See Long-term Benefits with Mavenclad, Merck Extension Study Confirms|